JEV E Glycoprotein Mutagenesis for Neurovirulence Mechanism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The molecular basis of neurovirulence in Japanese encephalitis virus (JEV) remains unclear, particularly for the live-attenuated SA14-14-2 vaccine strain, which has been administered to over 300 million children without comprehensive understanding of its attenuation mechanisms.
Innovation Solution
Construction of infectious cDNA clones for JEV SA14 and SA14-14-2, followed by rescue of molecularly cloned viruses, identified a single G1708→A substitution in the E glycoprotein that confers lethal neurovirulence, and site-directed mutagenesis demonstrated a novel regulatory role of E-244 in the ij hairpin of the E glycoprotein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If live-attenuated vaccine strain SA14-14-2 is administered to children, then immunity protection is provided, but the molecular mechanism of attenuation remains unclear
Solution Approach 1:
The patent segments the viral genome into individual open reading frames (ORFs) and expresses them separately in bacterial systems. By cloning and expressing each JEV ORF independently, the researchers can systematically identify which specific viral proteins or genetic elements are responsible for neurovirulence versus attenuation, thereby uncovering the molecular mechanisms while maintaining vaccine efficacy.
Solution Approach 2:
The patent uses bacterial expression systems as intermediaries to produce recombinant viral proteins. By expressing JEV proteins in E. coli and other bacterial hosts, the researchers can purify and characterize individual viral components to understand their role in virulence and attenuation without requiring complex eukaryotic cell cultures, thus bridging the gap between genetic sequence and functional understanding.
2Loss of information
If molecular cloning of JEV is performed to identify neurovirulence mechanisms, then scientific understanding is improved, but complex laboratory procedures are required
Solution Approach 1:
The patent employs self-assembling viral particles formed by co-expression of structural proteins (C, prM, and E proteins) in bacterial systems. The viral proteins automatically assemble into infectious-like particles without requiring complex eukaryotic cellular machinery, simplifying the experimental procedures while enabling detailed molecular analysis of neurovirulence mechanisms.
Solution Approach 2:
The patent creates simplified bacterial-based copies of viral components that replicate the essential functions of the original virus. By producing recombinant JEV proteins and self-assembling particles in bacteria, researchers can study viral mechanisms using easier-to-manipulate bacterial systems that copy the critical features of the viral replication and assembly processes.
3Ease of manufacture
If recombinant viral proteins are expressed in bacterial systems, then production is simplified, but protein folding and assembly challenges arise
Solution Approach 1:
The patent optimizes expression parameters such as temperature, induction timing, and host strain selection to facilitate proper protein folding in bacterial systems. By controlling these parameters, the researchers enable correct disulfide bond formation and tertiary structure development of viral proteins like E and prM, which are critical for their function and assembly into infectious particles.
Solution Approach 2:
The patent utilizes composite bacterial-viral hybrid systems where bacterial cellular machinery produces viral proteins that then self-assemble into virus-like particles. This composite approach combines the manufacturing simplicity of bacterial expression with the functional complexity of viral structures, allowing proper folding and assembly through the natural self-organizing properties of the viral proteins.
Data Source
AI summary
A group of mosquito-borne flaviviruses that cause fatal encephalitis in humans is among the most important of all emerging human pathogens of global significance. This group includes Japanese encephalitis virus (JEV), West Nile virus, St. Louis encephalitis virus, and Murray Valley encephalitis virus. In the present disclosure, the first reverse genetics system has been developed for SA14-14-2, a live JE vaccine that is most commonly used in most JE-endemic areas, by constructing an infectious bacterial artificial chromosome that contains the full-length SA14-14-2 cDNA. Using this infectious SA 14-14-2 cDNA, combined with a mouse model for JEV infection, a key viral neurovirulence factor has been discovered that is a conserved single amino acid in the ij hairpin adjacent to the fusion loop of the viral E glycoprotein, which regulates viral infectivity into neurons within the central nervous system.